Zhaoke Ophthalmology Ltd. (HK:6622)
:6622
Want to see HK:6622 full AI Analyst Report?
6622 Stock Chart & Stats
HK$3.17
HK$0.01(0.78%)
At close: 4:00 PM EST
HK$3.17
HK$0.01(0.78%)
Day’s Range― - ―
52-Week RangeHK$2.38 - HK$4.60
Previous CloseN/A
Volume310.50K
Average Volume (3M)1.25M
Market Cap
HK$1.40B
Enterprise ValueHK$198.41M
Total Cash (Recent Filing)HK$1.30B
Total Debt (Recent Filing)HK$292.48M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding548,749,000
10 Day Avg. Volume1,172,850
30 Day Avg. Volume1,251,992
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)0.92
Price to Sales (P/S)46.69
P/FCF Ratio-5.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)HK$421.50M
Bulls Say, Bears Say
Bulls Say
Supportive Balance SheetA modest leverage profile and a sizable equity base provide a durable financial cushion that lowers near-term insolvency risk and gives management flexibility to fund R&D or commercialization. This structural strength supports execution over the next several quarters without immediate balance-sheet pressure.
Ophthalmology-focused Business ModelA clear, specialized focus on ophthalmology and a hybrid in-house plus in-licensing model create lasting advantages: domain expertise, targeted regulatory pathways, and multiple routes to expand the product portfolio. This structural positioning improves partnerability and market-entry efficiency over months to years.
Improving Free Cash Flow TrendAn improving FCF trend, even from a negative base, signals early progress in cost control or revenue mix shifts and reduces the marginal funding need. If sustained, this durable trajectory can materially lower financing frequency and dilution risk across the next 2–6 months.
Bears Say
Persistent Operating LossesMulti-year operating losses indicate the business has not demonstrated a scalable profit model. Persistent deficits erode equity, increase reliance on external capital, and constrain strategic options, posing a lasting execution and financing risk if profitability is not achieved.
Negative Gross Profit In 2025A negative gross profit is a structural red flag: unit economics are currently unsustainable, meaning core product costs exceed revenues. This undermines the path to positive margins and requires durable cost or pricing fixes to restore business viability over the medium term.
Sustained Cash Burn And Funding RiskChronic operating cash burn necessitates recurring external financing or debt, creating dilution or leverage risk. Ongoing negative cash flow limits ability to invest in commercialization and R&D, making execution dependent on successful capital raises or material operational improvement.
Zhaoke Ophthalmology Ltd. News
6622 FAQ
What was Zhaoke Ophthalmology Ltd.’s price range in the past 12 months?
Zhaoke Ophthalmology Ltd. lowest stock price was HK$2.38 and its highest was HK$4.60 in the past 12 months.
What is Zhaoke Ophthalmology Ltd.’s market cap?
Zhaoke Ophthalmology Ltd.’s market cap is HK$1.40B.
When is Zhaoke Ophthalmology Ltd.’s upcoming earnings report date?
Zhaoke Ophthalmology Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 80 days.
How were Zhaoke Ophthalmology Ltd.’s earnings last quarter?
Zhaoke Ophthalmology Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.184 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.184.
Is Zhaoke Ophthalmology Ltd. overvalued?
According to Wall Street analysts Zhaoke Ophthalmology Ltd.’s price is currently Overvalued.
Does Zhaoke Ophthalmology Ltd. pay dividends?
Zhaoke Ophthalmology Ltd. does not currently pay dividends.
What is Zhaoke Ophthalmology Ltd.’s EPS estimate?
Zhaoke Ophthalmology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhaoke Ophthalmology Ltd. have?
Zhaoke Ophthalmology Ltd. has 548,749,000 shares outstanding.
What happened to Zhaoke Ophthalmology Ltd.’s price movement after its last earnings report?
Zhaoke Ophthalmology Ltd. reported an EPS of -HK$0.184 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.614%.
Which hedge fund is a major shareholder of Zhaoke Ophthalmology Ltd.?
Currently, no hedge funds are holding shares in HK:6622
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhaoke Ophthalmology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.41%
12-Months-Change
Fundamentals
Return on Equity
-12.64%
Trailing 12-Months
Asset Growth
-9.72%
Trailing 12-Months
Company Description
Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
Technical Analysis
Ocumension Therapeutics
―
TOT BIOPHARM International Co. Ltd.
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
Immunotech Biopharm Ltd
―